Announcing the Olink® Target 48 Mouse Cytokine Panel – the next generation in immunoassays designed to accelerate translational research.
19 Settembre 2023 - 9:00AM
Announcing the
Olink® Target 48
Mouse Cytokine Panel –
the next
generation in
immunoassays
designed to accelerate
translational research.
Discover more with less. Unmatched specificity
and sensitivity deliver translational insights from 1µl of
sample.
UPPSALA, Sweden, September 19, 2023 (GLOBE
NEWSWIRE) – Olink Holding AB (publ) (Nasdaq: OLK) today announced
the introduction of Olink® Target 48 Mouse Cytokine Panel, a
validated multiplexed protein panel that offers a detailed view of
the murine immune system, enabling in-depth disease modelling,
longitudinal studies and translational research.
The Olink Target 48 Mouse Cytokine Panel
represents a new standard in immunoassays giving researchers the
ability to accurately measure 43 carefully selected immune-related
proteins using as little as 1µl of sample volume. Offering
multiplexing with unparalleled specificity combined with high
sensitivity, the T48 Mouse Cytokine panel unlocks true longitudinal
studies over multiple timepoints in individual mice. The
transparent validation and streamlined workflow maintains the
exceptional standards of performance that users have come to expect
from Olink.
The addition of a targeted mouse panel with
absolute quantification capabilities adds to Olink`s broad
portfolio of proteomics solutions. From pre-clinical mouse models
to human clinical applications, Olink provides industry-leading
solutions encompassing all stages of drug development and disease
modelling.
“Olink Target 48 Mouse Cytokine Panel gives
scientists the ability to go deeper into preclinical and
translational disease research, tackling some of the most important
and challenging questions in biology,” said Jon Heimer, CEO
of Olink. “The potential this new product
brings to the market is exciting. Requiring minimal sample volume,
researchers can gain critical insights into the murine immune
system over time. Ultimately allowing for more accurate disease
modelling and accelerating drug development.”
Olink worked closely with leading researchers to
validate the performance of the panel. “We had the privilege of
being an early user of the Olink Target 48 Mouse Cytokine panel and
were especially impressed with the data produced using our murine
samples” said Cuong Nguyen, Associate
Professor, Department of Infectious Diseases and Immunology,
University of Florida. “What stood out was the remarkable
quality of the data it provided. Through its higher multiplexing
design, we extracted meaningful results from a comprehensive range
of over 40 immune-related biomarkers, all with remarkably minuscule
volumes of sera. The sensitivity of the assay undoubtedly
sets a new standard. Its performance surpasses other platforms
available in the market that we have tried.”
The Olink Target 48 Mouse Cytokine Panel was
designed to deliver an in-depth view of cytokine signalling and
inflammatory pathways for pre-clinical and translational research.
It can be utilized across key application areas to deepen current
understanding of molecular pathways involved in the disease
initiation and progression. Olink Target 48 Mouse Cytokine Panel is
fully compatible with the Olink®
Signature Q100, a high performance,
auto-calibrated instrument for data readout that facilitates
unattended operation. Work efficiency is further increased by the
streamlined assay workflow with minimal hands-on time.
More details are available on the Olink
website.
Investor contact Jan Medina, CFAVP Investor
Relations & Capital MarketsMobile: +1 617 802
4157jan.medina@olink.com
Media contact Michael B. Gonzales, PhDVP Global
MarketingMobile: +1 415 308 6467michael.gonzales@olink.com
About Olink Holding AB (publ)
(Nasdaq: OLK) is a company dedicated to accelerating proteomics
together with the scientific community, across multiple disease
areas to enable new discoveries and improve the lives of patients.
Olink provides a platform of products and services which are
deployed across major pharmaceutical companies and leading clinical
and academic institutions to deepen the understanding of real-time
human biology and drive 21st century healthcare through actionable
and impactful science. The Company was founded in 2016 and is well
established across Europe, North America and Asia. Olink is
headquartered in Uppsala, Sweden.
Forward-Looking StatementsThis
press release contains express or implied “forward-looking
statements” as defined under the Private Securities Litigation
Reform Act of 1995 that are based on management’s beliefs and
assumptions and on information currently available to management.
All statements contained in this release other than statements of
historical fact are forward-looking statements. In some cases, you
can identify forward-looking statements by the words “may,”
“might,” “will,” “could,” “would,” “should,” “expect,” “intend,”
“seek,” “plan,” “outlook,” “objective,” “anticipate,” “believe,”
“estimate,” “predict,” “project,” “potential,” “continue,”
“currently, “ongoing” or the negative of these terms or other
comparable terminology, although not all forward-looking statements
contain these words. These statements involve risks, uncertainties
and other factors that may cause actual results, levels of
activity, performance, or achievements to be materially different
from the information expressed or implied by these forward-looking
statements. These risks, uncertainties and other factors are
described under the caption “Risk Factors” in our Form 20-F for the
fiscal year ended December 31, 2022 (Commission file number
001-40277) and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections for the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Investor contact
Jan Medina, CFA
VP Investor Relations & Capital Markets
Mobile: +1 617 802 4157
jan.medina@olink.com
Media contact
Michael B. Gonzales, PhD
VP Global Marketing
Mobile: +1 415 308 6467
michael.gonzales@olink.com
Grafico Azioni Olink Holding AB (NASDAQ:OLK)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Olink Holding AB (NASDAQ:OLK)
Storico
Da Giu 2023 a Giu 2024